𝔖 Bobbio Scriptorium
✦   LIBER   ✦

In vivo and in vitro antitumor activity of oxaliplatin in combination with cetuximab in human colorectal tumor cell lines expressing different level of EGFR

✍ Scribed by Diane Balin-Gauthier; Jean-Pierre Delord; Philippe Rochaix; Valérie Mallard; Fabienne Thomas; Isabelle Hennebelle; Roland Bugat; Pierre Canal; Cuider Allal

Publisher
Springer
Year
2005
Tongue
English
Weight
521 KB
Volume
57
Category
Article
ISSN
0344-5704

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Selective antibody-mediated targeting of
Selective antibody-mediated targeting of class I MHC to EGFR-expressing tumor cells induces potent antitumor CTL activity in vitro and in vivo
✍ Hila Novak; Roy Noy; Kfir Oved; Dina Segal; Winfried S. Wels; Yoram Reiter 📂 Article 📅 2006 🏛 John Wiley and Sons 🌐 French ⚖ 276 KB 👁 1 views

## Abstract Epidermal growth factor receptor (EGFR) is highly overexpressed in many tumor types. We present a new fusion molecule that can target solid tumors that express EGFR. The fusion molecule combines the advantage(s) of the well‐established tumor targeting capabilities of high affinity recom

Antitumor activity of the selective epid
Antitumor activity of the selective epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) Iressa® (ZD1839) in an EGFR-expressing multidrug-resistant cell line in vitro and in vivo
✍ Ichiro Naruse; Tohru Ohmori; Yoko Ao; Hisao Fukumoto; Toshio Kuroki; Masatomo Mo 📂 Article 📅 2001 🏛 John Wiley and Sons 🌐 French ⚖ 216 KB 👁 1 views

## Abstract Selective tyrosine kinase inhibitors are regarded as promising antitumor agents for cancer treatment. Iressa® (ZD1839) is an orally active, selective EGFR‐TKI (epidermal growth factor receptor‐tyrosine kinase inhibitor) that blocks signal transduction pathways implicated in cancer cell